Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00050830 | A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer | PHASE2 | COMPLETED | 163 | — | — | Jan 1, 2003 | Nov 1, 2005 | Nov 8, 2006 | 57 | United States, Canada +6 |
| Name | Type | Description |
|---|---|---|
| CI 1033 | DRUG | - |
Inclusion Criteria: * Histologically or cytologically documented diagnosis of progressive or recurrent, locally advanced or metastatic NSCLC; a tumor that expresses at least one member of the erbB family of receptors; failed or relapsed after receiving a platinum-containing regimen as therapy; at l...